Effects of antihypertensive agents on the left ventricle:Clinical implications

American Journal of Cardiovascular Drugs

Volumn 1, Issue 4, 2001, Pages 263-279

  Díez, Javier ^a,b   González, Arantxa ^a   López, Begoña ^a   Ravassa, Susana ^a   Fortuño, María A ^a  

^a UNIVERSITY CLINIC OF NAVARRA   (Spain)

^b UNIVERSITY OF NAVARRA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHYPERTENSIVE AGENT;

ANIMAL; CLINICAL TRIAL; COMPARATIVE STUDY; DIASTOLE; DRUG EFFECT; GENE THERAPY; HEART LEFT VENTRICLE HYPERTROPHY; HEART VENTRICLE; HEART VENTRICLE REMODELING; HUMAN; HYPERTENSION; META ANALYSIS; MICROCIRCULATION; PATHOLOGY; PATHOPHYSIOLOGY; REVIEW; SYSTOLE;

ANIMALS; ANTIHYPERTENSIVE AGENTS; CLINICAL TRIALS; DIASTOLE; GENE THERAPY; HEART VENTRICLES; HUMANS; HYPERTENSION; HYPERTROPHY, LEFT VENTRICULAR; META-ANALYSIS; MICROCIRCULATION; SYSTOLE; VENTRICULAR REMODELING;

EID: 1842564208     PISSN: 11753277     EISSN: 1179187X     Source Type: Journal    
DOI: 10.2165/00129784-200101040-00005     Document Type: Review

References (211)

1. Frohlich ED, Apstein C, Chobanian AV, et al. The heart in hypertension. N Engl J Med 1992; 327: 998-1008
2. Menotti A, Keys A, Blackburn H, et al. Comparison of multivariate predictive power of major risk factors for coronary heart disease in different countries: results from eight nations of the Seven Countries Study, 25-year follow-up. J Cardiovasc Risk 1996; 3: 69-75
3. van der Hoogen PCW, Feskens EJM, Nagelkerke NJD, et al. The relation between blood pressure and mortality due to coronary heart disease among men in different parts of the world. New Engl J Med 2000; 342: 1-8
4. Lip GYH, Felmeden DC, Li-Saw-Hee FL, et al. Hypertensive heart disease. A complex syndrome or a hypertensive cardiomyopathy? Eur Heart J 2000; 21: 1653-65
5. Coca A, Gabriel R, de la Figuera M, et al. The impact of different echocardiographic diagnostic criteria on the prevalence of left ventricular hypertrophy in essential hypertension: the VITAE study. J Hypertens 1999; 17: 1471-80
6. Phillips RA, Diamond JA. Left ventricular hypertrophy, congestive heart failure, and coronary flow reserve abnormalities in hypertension. In: Oparil S, Weber MA, editors. Hypertension. Philadelphia: W.B. Saunders Company, 2000: 244-77
7. Lewis JF, Maron BJ. Diversity of patterns of hypertrophy in patients with systemic hypertension and marked left ventricular wall thickening. Am J Cardiol 1990; 65: 874-81
8. Grossman W, Jones D, McLaurin LP. Wall stress and patterns of hypertrophy in human left ventricle. J Clin Invest 1975; 56: 56-64
9. Ganau A, Devereux RB, Roman MJ, et al. Patterns of left ventricular hypertrophy and geometric remodeling in essential hypertension. J Am Coll Cardiol 1992; 19: 1550-8
10. Savage DD, Garrison RJ, Kannel WB, et al. The spectrum of left ventricular hypertrophy in a general population sample: The Framingham Study. Circulation 1987; 75: I26-I33
11. Liebson PR, Grandits G, Prineas R, et al. Echocardiographic correlates of left ventricular structure among 844 mildly hypertensive men and women in the Treatment of Mild Hypertension Study (TOMHS). Circulation 1993; 87: 476-86
12. Dunn FG, Oigman W, Sungard-Rise K, et al. Racial differences in cardiac adaptation to essential hypertension determined by echocardiographic indexes. J Am Coll Cardiol 1983; 5: 1348-51
13. Hammond IW, Alderman MH, Devereux RB, et al. Contrast in cardiac anatomy and function between black and white patients with hypertension. J Natl Med Assoc 1984; 76: 247-55
14. Mayet J, Shahi M, Foale RA, et al. Racial differences in cardiac structure and function in essential hypertension. BMJ 1994; 308: 1011-4
15. Hinderliter AL, Light KC, Willis PW. Racial differences in left ventricular structure in healthy young adults. Am J Cardiol 1992; 69: 1196-9
16. Harshfield GA, Alpert BS, Willey ES, et al. Race and gender influence ambulatory blood pressure patterns of adolescents. Hypertension 1989; 14: 598-603
17. Krumholz HM, Larson M, Levy D. Sex differences in cardiac adaptation to isolated systolic hypertension. Am J Cardiol 1993; 72: 310-3
18. Armario P, Hernández del Rey R, Sánchez P, et al. Determinants of left ventricular mass in untreated mildly hypertensive subjects. Hospitalet Study in Mild Hypertension. Am J Hypertens 1999; 12: 1084-90
19. Lauer MS, Anderson KM, Levy D. Influence of contemporary versus 30-year blood pressure levels on left ventricular mass and geometry. The Framingham Heart Study. J Am Coll Cardiol 1991; 18,5: 1287-94
20. Devereux RB, Pickering TG, Harshfield GA, et al. Left ventricular hypertrophy in patients with hypertension: Importance of blood pressure response to regular recurring stress. Circulation 1983; 68: 470-6
21. Ganau A, Devereux RB, Pickering TG, et al. Relation of left ventricular hemodynamic load and contractile performance to left ventricular mass in hypertension. Circulation 1990; 81: 25-36
22. Jones EC, Devereux RB, O?Grady MJ, et al. Relation of hemodynamic volume load to arterial and cardiac size. J Am Coll Cardiol 1997; 29; 1303-10
23. Lauer MS, Anderson Km, Levy D. Separate and joint influences of obesity and mild hypertension on left ventricular mass and geometry: The Framingham Heart Study. J Am Coll Cardiol 1992; 19; 130-4
24. De Simone G, Devereux RB, Roman MJ, et al. Relation of obesity and gender to left ventricular hypertrophy in normotensive and hypertensive adults. Hypertension 1994; 23: 600-6
25. Lim MJ, Barkan AL, Buda AJ. Rapid reduction of left ventricular hypertrophy in acromegaly after supression of growth hormone hypersecretion. Ann Intern Med 1992; 117: 719-26
26. Andronico G, Mangano M-T, Nardi E, et al. Insulin-like growth factor 1 and sodium-lithium countertransport in essential hypertension and in hypertensive left ventricular hypertrophy. J Hypertens 1993; 11: 1097-101
27. Douglas PS, Katz SE, Weinberg EO, et al. Hypertrophic remodeling: Gender differences in the early response to left ventricular pressure overload. J Am Coll Cardiol 1998; 32: 1118-25
28. Hinderliter AL, Light KC, Park WWIV. Gender differences in left ventricular structure and function in young adults with normal or marginally elevated blood pressure. Am J Hypertens 1992; 5: 33-6
29. Savage DD, Drayer JIM, Henry WL, et al. Echocardiographic assessment of cardiac anatomy and function in hypertensive patients. Circulation 1979; 59: 623-32
30. Levy D, Garrison RJ, Savage DD, et al. Left ventricular mass and incidence of coronary heart disease in an elderly cohort: The Framingham Heart Study. Ann Intern Med 1989; 110: 101-7
31. Marban E, Koretsune Y. Cell calcium, oncogenes, and hypertrophy. Hypertension 1990; 15: 652-8
32. Molkentin JD, Lu JR, Antos CL, et al. A calcineurin-dependent transcriptional pathway for cardiac hypertrophy. Cell 1998; 93: 215-28
33. Phillips RA, Krakoff LR, Ardeljan M, et al. Relation of left ventricular mass to insulin resistance and blood pressure in non-obese subjects. J Am Coll Cardiol 1994; 23: 48
34. Phillips RA, Krakoff LR, Dunaif A, et al. Relation among left ventricular mass, insulin resistance, and blood pressure in non-obese subjects. J Clin Endocrinol Metab 1998; 83: 4284-8
35. Sadoshima J, Xu Y, Slayter HS, et al. Autocrine release of angiotensin II mediates stretch-induced hypertrophy of cardiac myocytes in vitro. Cell 1993; 75: 977-84
36. Schmieder RE, Langenfeld MR, Friedrich A, et al. Angiotensin II related to sodium excretion modulates left ventricular structure in human essential hypertension. Circulation 1996; 94: 1304-9
37. Manolio TA, Levy D, Garrison RJ, et al. Relation of alcohol intake to left ventricular mass: The Framingham Study. J Am Coll Cardiol 1991; 17 (3): 717-21
38. Devereux RB, Drayer JIM, Chien S, et al. Whole blood viscosity as a determinant of cardiac hypertrophy in systemic hypertension. Am J Cardiol 1986. 54; 592-5
39. Bauwens FR, Duprez DA, De Buyzere ML, et al. Influence of the arterial blood pressure and nonhemodynamic factors on left ventricular hypertrophy in moderate essential hypertension. Am J Cardiol 1991; 68: 925-9
40. Weber KT, Brilla CG. Pathological hypertrophy and cardiac interstitium. Fibrosis and the renin-angiotensin-aldosterone system. Circulation 1991; 83: 1849-65
41. Schmieder RE, Messerli FH, Garavaglia GE, et al. Dietary salt intake: A determinant of cardiac involvement in essential hypertension. Circulation 1988; 78: 951-6
42. De la Sierra A, Coca A, Paré JC, et al. Erythrocyte ion fluxes in essential hypertensive patients with left ventricular hypertrophy. Circulation 1993; 88: 1628-33
43. Schunkert H, Hense H-W, Holmer SR, et al. Association between a deletion polymorphism of the angiotensin-converting enzyme gene and left ventricular hypertrophy. N Engl J Med 1994; 330: 1634-8
44. Gharavi AG, Lipkowitz MS, Diamond JA, et al. Deletion polymorphism of the angiotensin-converting enzyme gene is independently associated with left ventricular mass and geometric remodeling in systemic hypertension. Am J Cardiol 1996; 77: 1315-19
45. Sen S, Tarazi RC, Khairallah PA, et al. Cardiac hypertrophy in spontaneously hypertensive rats. Circ Res 1974; 35: 775-81
46. Adams T, Yanowitz F, Fisher G, et al. Heritability of cardiac size: an echocardiographic and electrocardiographic study of monozygotic and dizygotic twins. Circulation 1985; 71: 39-44
47. Trimarco B, Ricciardelli B, DE Luca N, et al. Participation of endogenous catecholamines in the regulation of left ventricular mass in progeny of hypertensive parents. Circulation 1985; 72: 38-46
48. Nosadini R, Semplicini A, Fioretto P, et al. Sodium-lithium countertransport and cardiorenal abnormalities in essential hypertension. Hypertension 1991; 18: 191-8
49. Akhter SA, Milano CA, Shotwell KF, et al. Transgenic mice with cardiac overexpression of alpha1B-adrenergic receptors. In vivo alpha1-adrenergic receptormediated regulation of beta-adrenergic signaling. J Biol Chem 1997; 272: 21253-9
50. Choi DJ, Koch WJ, Hunter JJ, et al. Mechanism of beta-adrenergic receptor desensitization in cardiac hypertrophy is increased beta-adrenergic receptor kinase. J Biol Chem 1997; 272: 17223-9
51. Frohlich ED. Risks mechanisms in hypertensive heart disease. Hypertension 1999; 34: 782-9
52. Casale PN, Devereux RB, Milner M, et al. Value of echocardiographic measurements of left ventricular mass in predicting cardiovascular morbid events in hypertensive men. Ann Intern Med 1986; 105: 173-8
53. Levy D, Garrison RJ, Savage DD, et al. Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study. N Engl J Med 1990; 322: 1561-6
54. Bikkina M, Larson MG, Levy D. Asymptomatic ventricular arrhythmias and mortality risk in subjects with left ventricular hypertrophy. J Am Coll Cardiol 1993; 22: 1111-6
55. Cooper RS, Simmons BE, Castaner A, et al. Left ventricular hypertrophy is associated with worse survival independent of ventricular function and number of coronary arteries severely narrowed. Am J Cardiol 1990; 65: 441-5
56. Ghali JK, Liao Y, Simmons B, et al. The prognostic role of left ventricular artery disease. Ann Intern Med 1992; 117: 831-5
57. Levy D, Anderson KM, Savage D, et al. Echocardiographically detected left ventricular hypertrophy: Prevalence and risk factors. The Framingham Heart Study. Ann Intern Med 1988; 108: 7-13
58. Schillaci G, Verdecchia P, Porcellati C, et al. Continuous relation between left ventricular mass and cardiovascular risk in essential hypertension. Hypertension 2000; 35: 580-6
59. Koren MJ, Devereux RB, Casale PN, et al. Relation of left ventricular mass and geometry to morbidity and mortality in uncomplicated essential hypertension. Ann Intern Med 1991; 114: 345-52
60. Verdecchia P, Schillaci G, Borgioni C, et al. Adverse prognostic significance of concentric remodeling of the left ventricle in hypertensive patients with normal left ventricular mass. J Am Coll Cardiol 1995; 25: 871-8
61. Krumholz HM, Larson M, Levy D. Prognosis of left ventricular geometric patterns in the Framingham Heart Study. J Am Coll Cardiol 1995; 25: 879-84
62. Ghali JK, Liao Y, Cooper RS. Influence of left ventricular geometric patterns on prognosis in patients with or without coronary artery disease. J Am Coll Cardiol 1998; 31: 1635-40
63. Nunez BD, Lavie CJ, Messerli FH, et al. Comparison of diastolic left ventricular filling and cardiac dysrhythmias in hypertensive patients with and without isolated septal hypertrophy. Am J Cardiol 1994; 74: 585-9
64. Phillips RA, Goldman ME, Ardlejan M, et al. Determinants of abnormal left ventricular filling in early hypertension. J Am Coll Cardiol 1989; 14: 979-85
65. Smith VE, Schulman P, Karimeddini M, et al. Rapid ventricular filling in left ventricular hypertrophy. II. Pathological hypertrophy. J Am Coll Cardiol 1985; 5: 869-74
66. Snider AR, Gidding SS, Rocchini AP, et al. Doppler evaluation of left ventricular diastolic filling in children with systemic hypertension. Am J Cardiol 1985; 56: 921-6
67. Phillips RA, Coplan NL, Krakoff LR, et al. Doppler echocardiographic analysis of left ventricular filling in treated hypertensive patients. J Am Coll Cardiol 1987; 9: 317-22
68. Dianzumba SB, DiPette DJ, Cornman C, et al. Left ventricular filling characteristics in mild untreated hypertension. Hypertension 1986; 8 Suppl. I: I156-I60
69. Inouye I, Massie B, Loge D, et al. Abnormal left ventricular filling: An early finding in mild to moderate systemic hypertension. Am J Cardiol 1984; 53: 120-6
70. Shapiro LM, McKenna WJ. Left ventricular hypertrophy: Relationship of structure to diastolic function in hypertension. Br Heart J 1984; 51: 637-42
71. Hartford M, Wikstrand J, Wallentin I, et al. Diastolic function of the heart in untreated primary hypertension. Hypertension 1984; 6: 329-38
72. Fouad FM, Slominski JM, Tarazi RC. Left ventricular diastolic function in hypertension: Relation to left ventricular mass and systolic function. J Am Coll Cardiol 1984; 3: 1500-6
73. Smith VE, White WB, Meeran MK, et al. Improved left ventricular filling accompanies reduced left ventricular mass during therapy of essential hypertension. J Am Coll Cardiol 1986; 8: 1449-54
74. Schulman SP, Weiss JL, Becher LC, et al. The effects of antihypertensive therapy on left ventricular mass in elderly patients. N Engl J Med 1990; 322: 1350-6
75. Phillips RA, Ardeljan M, Shimabukuro S. Normalization of left ventricular mass and associated changes in neurohormones and atrial natriuretic peptide after 1 year of sustained nifedipine therapy for severe hypertension. J Am Coll Cardiol 1991; 17: 1595-602
76. White WB, Schulman P, Karimeddini MK, et al. Regression of left ventricular mass is accompanied by improvement in rapid left ventricular filling following antihypertensive therapy with metoprolol. Am Heart J 1989; 117: 145-50
77. Trimarco B, DeLuca N, Rosiello G. Improvement of diastolic function after reversal of left ventricular hypertrophy induced by long-term antihypertensive treatment with tertatolol. Am J Cardiol 1989; 64: 745-51
78. González-Fernández RB, Altieri PI, D?az LM, et al. Effects of enalapril on heart failure in hypertensive patients with diastolic dysfunction. Am J Hypertens 1992; 5: 480-3
79. Shahi M, Thorn S, Poulter N, et al. Regression of hypertensive left ventricular hypertrophy and left ventricular diastolic dysfunction. Lancet 1990; 336: 458-61
80. Jalil JE, Doering CW, Janicki JS, et al. Fibrillar collagen and myocardial stiffness in the intact hypertrophied rat left ventricle. Circ Res 1989; 64: 1041-50
81. Abrahams C, Janicki JS, Weber KT. Myocardial hypertrophy in Macaca fascicularis: structural remodeling of the collagen matrix. Lab Invest 1987; 56: 676-83
82. Weber KT, Janicki, JS, Shroff SG, et al. Collagen remodeling of the pressureoverloaded, hypertrophied nonhuman primate myocardium. Circ Res 1988; 62: 757-65
83. Pearlman ES, Weber KT, Janicki JS, et al. Muscle fiber orientation and connective tissue content in the hypertrophied human heart. Lab Invest 1982; 46: 158-64
84. Weber KT, Janicki JS, Pick R, et al. Myocardial fibrosis and pathologic hypertrophy in the rat with renovascular hypertension. Am J Cardiol 1990; 65 Suppl.: 1G-7G
85. Brilla CG, Janicki JS, Weber KT. Cardioreparative effects of lisinopril in rats with genetic hypertension and left ventricular hypertrophy. Circulation 1991; 83: 1771-9
86. Villari B, Campbell SE, Hess OM, et al. Influence of collagen network on left ventricular systolic and diastolic function in aortic valve disease. J Am Coll Cardiol 1993; 22: 1477-84
87. Lorell BH, Grice WN, Apstein CS. Influence of hypertension with minimal hypertrophy on diastolic function during demand ischemia. Hypertension 1989; 13: 361-70
88. Brutsaert DL, Rademakers FE, Sys SU, et al. Analysis of relaxation in the evaluation of ventricular function of the heart. Prog Cardiovasc Dis 1985; 28: 143-63
89. Schussheim AE, Diamond JA, Jhang JS, et al. Midwall fractional shortening is an independent predictor of left ventricular diastolic dysfunction in asymptomatic patients with systemic hypertension. Am J Cardiol 1998; 82: 1056-9
90. Topol EJ, Traill GV, Fortuin NJ. Hypertensive cardiomyopathy of the elderly. N Engl J Med 1985; 312: 277-82
91. Soufer R, Wohlgelernter D, Vita N, et al. Intact systolic left ventricular function in clinical congestive heart failure. Am J Cardiol 1985; 55: 1032-6
92. Bonow RO, Udelson JE. Left ventricular diastolic dysfunction as a cause of congestive heart failure: Mechanisms and management. Ann Intern Med 1992; 117: 502-10
93. Cuocolo A, Sax FL, Brush JE, et al. Left ventricular hypertrophy and impaired diastolic filling in essential hypertension: Diastolic mechanisms for systolic dysfunction during exercise. Circulation 1990; 81: 978-86
94. Gandhi SK, Powers JC, Nomeir A-M, et al. The pathogenesis of acute pulmonary edema associated with hypertension. N Engl J Med 2001; 344: 17-22
95. Senni M, Tribouilloy CM, Rodeheffer RJ, et al. Congestive heart failure in the community. Circulation 1998; 98: 2282-9
96. Hartford M, Wikstrand JC, Wallentin I, et al. Left ventricular wall stress and systolic function in untreated primary hypertension. Hypertension 1985; 7: 97-104
97. De Simone G, Devereux RB, Koren MJ, et al. Midwall left ventricular mechanics. An independent predictor of cardiovascular risk in arterial hypertension. Circulation 1996; 93: 259-65
98. Wachtell K, Rokkedal J, Bella JN, et al. Effect of electrocardiographic left ventricular hypertrophy on left ventricular systolic function in systemic hypertension (the LIFE study). Am J Cardiol 2001; 87: 54-60
99. De Simone G, Devereux RB, Roman MJ, et al. Assessment of left ventricular function by the midwall fractional shortening/end-systolic stress relation in human hypertension. J Am Coll Cardiol 1999; 23: 1444-51
100. Schilacci G, Verdecchia P, Reboldi G, et al. Subclinical left ventricular dysfunction in systemic hypertension and the role of 24-hour blood pressure. Am J Cardiol 2000; 86: 509-13
101. Lund DD, Tomanek RJ. Myocardial morphology in spontaneously hypertensive and aortic-constricted rats. Am J Anat 1978; 152: 141-51
102. Rakusan K, du Mesnil de Rochemont W, Braasch W, et al. Capacity of the terminal vascular bed during normal growth, in cardiomegaly, and in cardiac atrophy. Circ Res 1967; 21: 209-15
103. Marcus ML, Harrison DG, Chilian WM, et al. Alterations in the coronary circulation in hypertrophied ventricles. Circulation 1987; 75 Suppl. I: I19-I25
104. Breisch EA, White FC, Bloor CM. Myocardial characteristics of pressure overload hypertrophy: a structural and functional study. Lab Invest 1984; 51: 333-42
105. Tomanek RJ, Palmer PJ, Peiffer GL, et al. Morphometry of canine coronary arteries, arterioles, and capillaries during hypertension and left ventricular hypertrophy. Circ Res 1986; 58: 38-46
106. Harrison DG, Barnes DH, Hiratzka LF, et al. The effect of cardiac hypertrophy on the coronary collateral circulation. Circulation 1985; 71: 1135-45
107. Noon JP, Walker BR, Webb DJ, et al. Impaired microvascular dilatation and capillary rarefaction in young adults with a predisposition to high blood pressure. J Clin Invest 1997; 99: 1873-9
108. Strauer BE. The concept of coronary flow reserve. J Cardiovasc Pharmacol 1992; 1 Suppl. 5: S67-S80
109. Schwartzkopff B, Motz W, Knauer S, et al. Morphometric investigation of intramyocardial arterioles in right septal endomyocardial biopsy of patients with arterial hypertension and left ventricular hypertrophy. J Cardiovasc Pharmacol 1992; 20: 2-7
110. Brush JE, Faxon DP, Salmon S, et al. Abnormal endothelium-dependent coronary vasomotion in hypertensive patients. J Am Coll Cardiol 1992; 19: 809-15
111. Houghton JL, Frank MJ, Carr AA, et al. Relations among impaired coronary flow reserve, left ventricular hypertrophy and thallium perfusion defects in hypertensive patients without obstructive coronary artery disease. J Am Coll Cardiol 1990: 15: 43-51
112. Mosterd A, D?Agostino RB, Silbershatz H, et al. Trends in the prevalence of hypertension, antihypertensive therapy, and left ventricular hypertrophy. N Engl J Med 1999; 340: 1221-7
113. Devereux RB. Regression of left ventricular hypertrophy. How and why? JAMA 1996; 275: 1517-8
114. Sheridan DJ. Regression of left ventricular hypertrophy: do antihypertensive classes differ? J Hypertens 2000; 18 Suppl. 3: S21-7
115. Liebson PR. Clinical studies of drug reversal of hypertensive left ventricular hypertrophy. Am J Hypertens 1990; 3: 512-7
116. Dahlöf B, Pennert K, Hansson L. Reversal of left ventricular hypertrophy in hypertensive patients. A metaanalysis of 109 treatment studies. Am J Hypertens 1992; 5: 95-110
117. Cruickshank JM, Lewis J, Moore V, et al. Reversibility of left ventricular hypertrophy by different types of antihypertensive therapy. J Hum Hypertens 1992; 6: 85-90
118. Agabiti-Rosei E, Muiesan ML. Left ventricular hypertrophy: how to influence an important risk factor in hypertension. J Hypertens 1998; 16 Suppl. 1: S53-8
119. Schmieder RE, Schlaich MP, Klingbeil AU, et al. Update on reversal of left ventricular hypertrophy in essential hypertension (a meta-analysis of all randomized double-blind studies until December 1996). Nephrol Dial Transplant 1998; 13: 564-9
120. Fagard R, Lijnen P, Staessen J, et al. Mechanical and other factors relating to left ventricular hypertrophy. Blood Pressure 1994; 3 Suppl. 1: 5-10
121. Liebson PR, Grandits GA, Dianzumba S, et al. Comparison of five antihypertensive monotherapies and placebo for change in left ventricular mass in patients receiving nutritional-hygienic therapy in the Treatment of Mild Hypertension Study (TOMHS). Circulation 1995; 91: 698-706
122. Neaton JD, Grimm RH, Prineas RJ, et al., on behalf of Treatment of Mild Hypertension Study Research Group. Treatment of Mild Hypertension Study. Final results. JAMA 1993: 270; 713-24
123. Agabiti-Rosei E, Ambrosioni E, DalPalu? C, et al., on behalf of the RACE study group. ACE-inhibitor ramipril is more effective than ?-blocker atenolol in reducing left ventricular mass in hypertension. Results of the RACE (ramipril cardioprotective evaluation) study. J Hypertens 1995: 13; 1325-35
124. Terpstra WF, May JF, Smit AJ, et al. Long-term effects of amlodipine and lisinopril on left ventricular mass and diastolic function in elderly, previously untreated hypertensive patients: the ELVERA trial. J Hypertens 2001; 19: 303-9
125. Gottdiener J, Reda D, Massie BM, et al. Effect of single-drug therapy on reduction of left ventricular mass in mild to moderate hypertension: comparison of six antihypertensive agents. The Department of Veterans Affairs Cooperative study group on antihypertensive agents. Circulation 1997; 95: 2007-14
126. Kostis JB, Davis BR, Cutler J, et al. Prevention of heart failure by antihypertensive drug treatment in older persons with isolated systolic hypertension. SHEP Cooperative Research Group. JAMA 1997; 278: 212-6
127. Furberg CD, Cutler JA. Diuretic agents versus beta-blockers: comparison of effects on mortality, stroke, and coronary events. Hypertension 1989; 13: I57-I61
128. Curb JD, Pressel SL, Cutler JA, et al. Effect of diuretic-based antihypertensive treatment on cardiovascular disease risk in older diabetic patients with isolated systolic hypertension. Systolic Hypertension in the Elderly Program cooperative research group. JAMA 1996; 276: 1886-92
129. Pahor M, Guralnik JM, Corti MC, et al. Long-term survival and use of antihypertensive medications in older persons. J Am Geriatr Soc 1995; 43: 1191-7
130. Gosse P, Sheridan DJ, Zannad F, et al, on behalf of the LIVE investigators. Regression of left ventricular hypertrophy in hypertensive patients treated with indapamide SR 1.5 mg versus enalapril 20 mg: the LIVE study. J Hypertens 2000; 18: 1465-75
131. Delcayre C, Silvestre J-S, Garnier A, et al. Cardiac aldosterone production and ventricular remodeling. Kidney Int 2000; 57: 1346-51
132. Sato A, Suzuki Y, Saruta T. Effects of spironolactone and angiotensin-converting enzyme inhibitor on left ventricular hypertrophy in patients with essential hypertension Hypertens Res 1999: 22: 17-22
133. Thürmann PA, Kenedi P, Schmidt A, et al. Influence of the angiotensin II antagonist valsartan on left ventricular hypertrophy in patients with essential hypertension. Circulation 1998; 98: 2037-42
134. Cottone S, Vadal? A, Vella MC et al. Changes of plasma endothelin and growth factor levels, and of left ventricular mass, after chronic AT1-receptor blockade in human hypertension. Am J Hypertens 1998; 11: 548-53
135. Dahlöf B, Devereux R, Faire U, et al., for the LIFE study Group. The Losartan Intervention For Endpoint Reduction (LIFE) in hypertension study: rationale, design, and methods. Am J Hypertens 1997; 10: 705-13
136. Dahlöf B, Devereux RB, Julius S, et al., for the LIFE study Group. Characteristics of 9194 patients with left ventricular hypertrophy. The LIFE study. Hypertension 1998; 32: 989-97
137. Kjeldsen SE, Dahlöf B, Devereux RB, et al, for the LIFE study Group. Lowering of blood pressure and predictors of response in patients with left ventricular hypertrophy; the LIFE study. Am J Hypertens 2000; 13: 899-906
138. Schmieder RE, Schnieder MP, Martus P, et al. Reduction of left ventricular hypertrophy (LVH) by antihypertensive therapy: results of a meta-analysis of all double-blind randomized studies. J Am Coll Cardiol 2001; 37 (2 Suppl. A): 251A-262A
139. Farina NK, Johnston CI, Burrell LM. Reversal of cardiac hypertrophy and fibrosis by S21402, a dual inhibitor of neutral endopeptidase and angiotensin converting enzyme in SHRs. J Hypertens 2000; 18: 749-55
140. Burrell LM, Droogh J, Man in?t Veld O, et al. Antihypertensive and antihypertrophic effects of omapatrilat in SHR. Am J Hypertens 2000; 13: 1110-6
141. Levy D, Salomon M, D?Agostino R, et al. Prognostic implications of baseline electrocardiographic features and their serial changes in subjects with left ventricular hypertrophy. Circulation 1994; 90: 1786-93
142. Koren MJ, Savage DD, Casale PN, et al. Changes in left ventricular mass predict risk in essential hypertension [abstract]. Circulation 1990; 82 Suppl. III: III29
143. Yurenev AP, Dyakonova HG, Novikov ID, et al. Management of essential hypertension in patients with different degrees of left ventricular hypertrophy multicenter trial. Am J Hypertens 1992; 5 Suppl.: S182-9
144. Verdecchia P, Schillaci G, Borgioni C, et al. Prognostic significance of serial changes in left ventricular mass in essential hypertension. Circulation 1998; 97: 48-54
145. Muiesan ML, Salvetti M, Rizzoni D, et al. Association of change in left ventricular mass with prognosis during long term antihypertensive treatment. J Hypertens 1995; 13: 1091-5
146. MacMahon SW, Wilcken DEL, MacDonald GJ. The effect of weight reduction on left ventricular mass: a randomized controlled trial in young, overweight hypertensive patients. N Engl J Med 1986; 314: 334-9
147. Andren B, Lind L, Lithell H. The influence of different antihypertensive drugs on left ventricular hypertrophy in a population sample of elderly men. J Human Hypertens 1999; 13: 499-504
148. Franz IW, Ketelhut R, Behr U, et al. Time course of reduction in left ventricular mass during long term antihypertensive therapy. J Hum Hypertens 1994; 8: 191-8
149. Mancia G, Zanchetti A, Agabiti-Rosei E, et al., for the Sample Study Group. Ambulatory blood pressure is superior to clinic blood pressure in predicting treatment-induced regression of left ventricular hypertrophy. Circulation 1997; 95: 1464-70
150. Fagard RH, Staessen JA, Thijs L. Prediction of cardiac structure and function by repeated and ambulatory blood pressure. Hypertension 1997; 29: 22-9
151. Muiesan ML, Rizzoni D, Zulli R, et al. Regression of cardiac hypertrophy and nighttime blood pressure reduction. J Hypertens 1993; 11 Suppl. 5: S300-1
152. Palatini P, Penzo M, Raccioppa A, et al. Clinical relevance of nighttime blood pressure and daytime blood pressure variability. Arch Intern Med 1992; 152: 1855-60
153. Parati G, Pomidossi G, Albini F, et al. Relationship of 24 hour blood pressure mean and variability to severity of target organ damage in hypertension. J Hypertens 1987; 5: 93-8
154. Frattola A, Parati G, Cuspidi C, et al. Prognostic value of 24 hour blood pressure variability. J Hypertens 1991; 11: 1133-7
155. Bouthier JD, De Luca N, Safar ME, et al. Cardiac hypertrophy and arterial distensibility in essential hypertension. Am Heart J 1985; 109: 1345-52
156. De Luca N, Rosiello G, Lamenza F,. et al. Reversal of cardiac and large artery structural abnormalities induced by long-term antihypertensive treatment with trandolapril. Am J Cardiol 1992; 70: 52-9
157. Clements IP, Bailey KR, Zachariah PK. Effects of exercise and therapy on ventricular emptying and filling in mildly hypertensive patients. Am J Hypertens 1994; 7: 695-702
158. Nishimura RA, Schwartz RS, Holmes Jr DR, et al. Failure of calcium channel blockers to improve ventricular relaxation in humans. J Am Coll Cardiol 1993; 21: 182-8
159. Zusman RM, Christensen DM, Higgins J, et al. Nifedipine improves left ventricular function in patients with hypertension. J Cardiovasc Pharmacol 1991; 18: 843-8
160. Szlachcic J, Tubau JF, Vollmer C, et al. Effects of diltiazem on left ventricular mass and diastolic filling in mild to moderate hypertension. Am J Cardiol 1989; 63: 198-201
161. Zusman RM, Christensen DM, Federman EB, et al. Nifedipine but not propranolol, improves left ventricular systolic and diastolic function in patients with hypertension. Am J Cardiol 1989; 64: 51F-61F
162. Fouad FM, Slominski MJ, Tarazi RC, et al. Alterations in left ventricular filling with beta-adrenergic blockade. Am J Cardiol 1983; 51: 161-4
163. Schunkert H, Dzau VJ, Tang SS, et al. Increased rat cardiac angiotensin-converting enzyme activity and mRNA expression in pressure overload left ventricular hypertrophy. J Clin Invest 1990; 86: 1913-20
164. Esper RJ, Burrieza OH, Cacharrón JL, et al. Left ventricular mass regression and diastolic function improvement in mild and moderate hypertensive patients treated with lisinopril. Cardiology 1993; 83; 76-81
165. Grandi AM, Venco A, Barzizza F, et al. Effect of enalapril on left ventricular mass and performance in essential hypertension. Am J Cardiol 1989; 63: 1093-7
166. Muiesan ML, Agabiti-Rosei E, Romanelli G. Improved left ventricular systolic and diastolic function after regression of cardiac hypertrophy, treatment withdrawal, and redevelopment of hypertension. J Cardiovasc Pharmacol 1991; 17 Suppl. 2: S179-81
167. Gottdiener JS. Measuring diastolic function. J Am Coll Cardiol 1991; 18: 83-4
168. Clement D, DeBuyzere M, Dupres D. Left ventricular function and regression of left ventricular hypertrophy in essential hypertension. Am J Hypertens 1993; 6: 14S-9S
169. Khatri IM, Gottdiener JS, Notargiacomo AV, et al. The effects of therapy on left ventricular function in hypertension. Clin Sci 1980; 59: 435s-9s
170. Gottdiener JS. Clinical trials of single-drug therapy for the cardiac effects of hypertension. Am J Hypertens 1999; 12: 12S-8S
171. Oren S, Messerli FH, Grossman E, et al. Immediate and short-term cardiovascular effects of fosinopril, a new angiotensin-converting enzyme inhibitor, in patients with essential hypertension. J Am Coll Cardiol 1991; 17: 1183-7
172. Schussheim AE, Diamond JA, Phillips RA. Left ventricular midwall function improves with antihypertensive therapy and regression of left ventricular hypertrophy in patients with asymptomatic hypertension. Am J Cardiol 2001; 87: 61-5
173. Simone G, Palmieri V, Koren MJ, et al. Prognostic implication of the compensatory nature of left ventricular mass in arterial hypertension. J Hypertens 2001; 19: 119-25
174. Schelbert HR, Phelps ME, Huang S, et al. N-13 ammonia as an indicator of myocardial blood flow. Circulation 1981; 63: 1259-72
175. Anderson PG, Bishop SP, Digerness SB. Vascular remodelling and improvement of coronary reserve after hydralazine treatment in spontaneously hypertensive rats. Circ Res 1989; 64: 1127-36
176. Canby CA, Tomanek RJ. Role of lowering arterial pressure on maximal coronary flow with and without regression of cardiac hypertrophy. Am J Physiol 1989; 257: H1110-8
177. Ishihara K, Zile MR, Nagatsu M, et al. Coronary blood flow after the regression of pressure-overload left ventricular hypertrophy. Circ Res 1992; 71: 1472-81
178. Sato F, Isoyama S, Takishima T. Normalization of impaired coronary circulation in hypertrophied rat hearts. Hypertension 1990; 16: 26-34
179. Heagerty AM, Bund SJ, Aalkajaer C. Effects of drug treatment on human resistance arteriole morphology in essential hypertension: Direct evidence for structural remodelling of resistance vessels. Lancet 1988; II: 1209-12
180. Schwartzkopff B, Brehm M, Mundhenke M, et al. Repair of coronary arterioles after treatment with perindopril in hypertensive heart disease. Hypertension 2000; 36: 220-5
181. Motz WH, Strauer BE. Improvement of coronary flow reserve after long-term therapy with enalapril. Hypertension 1996; 27: 1031-8
182. Yamada H, Fabris B, Allen AM, et al. Localization of angiotensin- converting enzyme in the rat heart. Circ Res 1991; 68: 141-9
183. Rossen JD, Simonetti I, Marcus ML, et al. The effect of diltiazem on coronary flow reserve in humans. Circulation 1989; 80: 1240-6
184. Vrolix MC, Sionis D, Piessens J, et al. Changes in human coronary flow reserve after administration of intracoronary diltiazem. J Cardiovasc Pharmacol 1991; 18 Suppl. 9: S64-7
185. Diamond JA, Machac J, Henzlova MJ, et al. Effect of long-term calcium channel blocker antihypertensive therapy on coronary physiology. J Am Coll Cardiol 1994; 256A
186. Merrill G, Young M, Dorell S, et al. Coronary interactions between nifedipine and adenosine in the intact dog heart. Eur J Pharmacol 1982; 81: 543-50
187. Weber KT. Fibrosis and hypertensive heart disease. Curr Opin Cardiol 2000; 15: 264-72
188. Weber KT. Targeting pathological remodelling: Concepts of cardioprotection and reparation. Circulation 2000; 102: 1342-5
189. Brilla CG, Funck RC, Rupp H. Lisinopril-mediated regression of myocardial fibrosis in patients with hypertensive heart disease. Circulation 2000; 102: 1388-93
190. López B, Querejeta R, Varo N, et al. Usefulness of serum carboxy-terminal propeptide of procollagen type I to assess the cardioreparative ability of antihypertensive treatment in hypertensive patients. Circulation 2001; 109: 286-91
191. Picano E, Pelosi G, Marzilli M, et al. In vivo quantitative ultrasonic evaluation of myocardial fibrosis in humans. Circulation 1990; 81: 58-64
192. Ciulla M, Paliotti R, Hess DB, et al. Echocardiographic patterns of myocardial fibrosis in hypertensive patients: endomyocardial biopsy versus ultrasonic tissue characterization. J Am Soc Echocardiogr 1997; 10: 657-64
193. D?ez J, Laviades C. Monitoring fibrillar collagen turnover in hypertensive heart disease. Cardiovasc Res 1997; 35: 202-5
194. Laviades C, Mayor G, D?ez J. Treatment with lisinopril normalizes serum concentration of procollagen type III amino-terminal peptide in patients with essential hypertension. Am J Hypertens 1994; 7: 52-8
195. D?ez J, Laviades C, Mayor G, et al. Increased serum concentration of procollagen peptides in essential hypertension: relation to cardiac alterations. Circulation 1995; 91: 1450-6
196. Querejeta R, Varo N, López B, et al. Serum carboxy-terminal propeptide of procollagen type I is a marker of myocardial fibrosis in hypertensive heart disease. Circulation 2000; 101: 1729-35
197. Laviades C, Varo N, D?ez J. Transforming growth factor ? in hypertensives with cardiorenal damage. Hypertension 2000; 36: 517-22
198. Laviades C, Varo N, Fernández J, et al. Abnormalities of the extra-cellular degradation of collagen type I in essential hypertension. Circulation 1998; 98: 535-40
199. Turner ST, Boerwinkle E. Genetics of hypertension, target-organ complications, and response to therapy. Circulation 2000; 102: IV40-IV5
200. Post W, Larson M, Myers R, et al. The heritability of left ventricular mass: the Framingham Heart Study. Hypertension 1997; 30: 1025-8
201. Harshfield G, Grim C, Hwang C, et al. Genetic and environmental influences on echocardiographically determined left ventricular mass in black twins. Am J Hypertens 1990; 3: 538-43
202. Innes B, McLaughlin M. Independent genetic susceptibility to cardiac hypertrophy in inherited hypertension. Hypertension 1998; 31: 741-6
203. Costerousse O, Allegrini J, López M, et al. Angiotensin I-converting enzyme in human circulating mononuclear cells: Genetic polymorphism of expression in T-lymphocytes. Biochem J 1993; 290: 33-40
204. Tiret L, Rigat B, Visvikis S, et al. Evidence, from combined segregation and linkage analysis, that a variant of the angiotensin I converting enzyme (ACE) gene controls plasma ACE levels. Am J Hum Genet 1992; 51: 197-205
205. Kuznetsova T, Staessen JA, Wang JG, et al. Antihypertensive treatment modulates the association between the D/I ACE gene polymorphism and left ventricular hypertrophy: a meta-analysis. J Hum Hypertens 2000; 14: 447-54
206. Ferrari P. Pharmacogenomics: a new approach to individual therapy of hypertension ? Curr Opin Nephrol Hypertens 1998; 7: 217-22
207. Pratt RE, Dzau VJ. Genomics and hypertension: Concepts, potentials, and opportunities. Hypertension 1999; 33 (Part II): 238-47
208. Sasaki M, Oki T, Iuchi A, et al. Relationship between the angiotensin converting enzyme gene polymorphism and the effects of enalapril on left ventricular hypertrophy and impaired diastolic filling in essential hypertension: M-mode and pulsed Doppler echocardiographic studies. J Hypertens 1996; 14: 1403-8
209. Hernández D, Lacalzada J, Salido E, et al. Regression of left ventricular hypertrophy by lisinopril after renal transplantation: Role of ACE gene polymorphism. Kidney Int 2000; 58: 889-97
210. Cannella G, Paoletti E, Barocci S, et al. Angiotensin-converting enzyme gene polymorphism and reversibility of uremic left ventricular hypertrophy following long-term antihypertensive therapy. Kidney Int 1998; 54: 618-26
211. Kohno M, Yokokawa K, Minami M, et al. Association between angiotensinconverting enzyme gene polymorphism and regression of left ventricular hypertrophy in patients treated with angiotensin-converting enzyme inhibitors. Am J Med 1999; 106: 544-9